52 Week Range
As of on the NASDAQ ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Merrimack Pharmaceuticals Q2 Loss Per Share $0.06
Merrimack Pharmaceuticals Q3 Loss Per Share $0.08
Merrimack Reports Q2 Loss Per Share Of $0.09
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is entitled to receive contingent milestone payments related to its sale of ONIVYDE to Ipsen S.A. ONIVYDE is approved by the Unites States Food and Drug Administration (FDA) in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. The Company does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets.
Biotechnology & Drugs
1 Broadway Fl 14
Gary L. Crocker
Chairman of the Board, President, Treasurer
Eric D. Andersen
Noah G. Levy
Ulrik B. Nielsen
Russell T. Ray
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
The 1st U.S. Circuit Court of Appeals on Friday upheld the convictions and prison sentences of former Akebia Therapeutics Inc and Merrimack Pharmaceuticals Inc employees who were found to have taken part in an insider trading scheme.
* AS OF MARCH 31, HAD CASH AND CASH EQUIVALENTS AND INVESTMENTS OF $18.0 MILLION Source text for Eikon: Further company coverage:
* MERRIMACK DIVESTS EARLY STAGE ASSET FOR $2.25 MILLION; PROVIDES STRATEGY UPDATE
* MERRIMACK PHARMACEUTICALS INC - ENTERED INTO AN ASSET PURCHASE AGREEMENT WITH CELATOR PHARMACEUTICALS, INC.
A former Merrimack Pharmaceuticals Inc employee was sentenced on Tuesday to six months in prison after being convicted of participating in an insider trading scheme with a friend at a rival biopharmaceutical company.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.